Malawi vs Somalia: Average cost of multi drug-resistant tuberculosis treatment
Malawi
1,246 constant 2022 US$
in 2024
Somalia
1,178 constant 2022 US$
in 2021
Malawi rank
38th
Somalia rank
40th
Average cost of multi drug-resistant tuberculosis treatment over time
- Malawi
- Somalia
How they compare
Malawi currently reports 1,246 constant 2022 US$ against 1,178 constant 2022 US$ in Somalia, a difference of 68 constant 2022 US$.
That makes Malawi's figure about 1.1 times Somalia's.
Across all 5 years both countries report, Malawi has been ahead every year.
Malawi ranks 38th and Somalia ranks 40th of 92 countries.
Malawi has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Malawi | Somalia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,631 constant 2022 US$ | 1,490 constant 2022 US$ | 1,141 constant 2022 US$ | Malawi |
| 2020s | 2,399 constant 2022 US$ | 1,340 constant 2022 US$ | 1,058 constant 2022 US$ | Malawi |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Malawi or Somalia?
- Malawi, at 1,246 constant 2022 US$ against 1,178 constant 2022 US$ in Somalia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Malawi and Somalia?
- 68 constant 2022 US$, with Malawi ahead.
- How many years of comparable data are there for Malawi and Somalia?
- 5 years are reported by both, from 2017 to 2021.
- How do Malawi and Somalia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Malawi ranks 38th and Somalia ranks 40th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.